This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Back to Drawing Board for Gilead

Gilead Sciences' (GILD - Get Report) combination of two HIV drugs failed bioequivalence tests, sending the company's shares lower after the market closed Tuesday.

Gilead shares sank nearly 5% to $40.70 after hours. According to the company, a pill combining Gilead's Truvada and Bristol-Myers Squibb's (BMY - Get Report) Sustiva didn't provide the same medication levels in a patient's blood as separate doses of each drug would.

In April, Gilead said it failed in its first attempt at combining the drugs. The company plans to evaluate up to three new formulations. Bioequivalence and stability studies of these new formulations will be conducted in the next few months.

Pending the results of the studies, Gilead and Bristol-Myers Squibb expect to file a new drug application with the Food and Drug Administration in the first half of 2006. If approved, the new pill would be the first complete treatment regimen of its kind available in a fixed-dose combination taken once a day.

Bristol-Myers shares were down a penny to $25.10.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BMY $65.80 -0.30%
GILD $103.70 -1.44%
AAPL $130.28 0.47%
FB $81.53 -1.07%
GOOG $565.06 3.30%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs